NCT02589522View on ClinicalTrials.gov

Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 22, 2017

Primary Completion Date

August 23, 2021

Study Completion Date

September 18, 2026

Conditions
Metastatic Lung Neuroendocrine NeoplasmMetastatic Lung Non-Small Cell CarcinomaMetastatic Lung Small Cell CarcinomaMetastatic Malignant Neoplasm in the BrainStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8
Interventions
DRUG

Berzosertib

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

RADIATION

Whole-Brain Radiotherapy

Undergo whole-brain radiation therapy

Trial Locations (9)

21201

University of Maryland/Greenebaum Cancer Center, Baltimore

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

40536

University of Kentucky/Markey Cancer Center, Lexington

44106

Case Western Reserve University, Cleveland

55905

Mayo Clinic in Rochester, Rochester

63110

Washington University School of Medicine, St Louis

91010

City of Hope Comprehensive Cancer Center, Duarte

95817

University of California Davis Comprehensive Cancer Center, Sacramento

32224-9980

Mayo Clinic in Florida, Jacksonville

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH